Bioventus Inc. · NASDAQ:BVS
Bioventus — J.P. Morgan Healthcare Conference 2022
15 slides from Bioventus's conference presentation, January 2022
Slide 1: Innovations for Active Healing
INNOVATIONS FOR ACTIVE HEALING J.P. Morgan Healthcare Conference Ken Reali January 2022 Chief Executive Officer
Slide 2: Forward-Looking Statements
Innovations For Active Healing Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentati
Slide 3: Bioventus Today
Innovations For Active Healing BIOVENTUS TODAY Our Products Treat 600,000 People Each Year 1 $500M 2021 Global Proforma Revenue Consistent High Strong Revenue Surgical 70s G Solutions Momentum: Pain ross Margin and Treatments 9% Five-year Strong Free net sales CAGR2 Restorative Cash Flow Therapies $
Slide 4: Strategic Building Blocks for Growth
Innovations For Active Healing STRATEGIC BUILDING BLOCKS FOR GROWTH Positioned to Benefit from Current and Expected Demographics and Tailwinds Across Call Points Pain Treatments Restorative Therapies Surgical Solutions Products General Call Point Sports Medicine Foot & Ankle Foot & Ankle Spine Neuro
Slide 5: Drivers for Shareholder Value Creation
Innovations For Active Healing DRIVERS FOR SHAREHOLDER VALUE CREATION CONSISTENT REVENUE MARGIN REPEATABLE FREE VALUE CREATING GROWTH EXPANSION CASH FLOW M&A Delivering double-digit Expanding operating margins Producing consistent free Enhancing scale and organic top-line growth through synergies, c
Slide 6: Driving Continued Double-Digit Growth
Innovations For Active Healing DRIVING CONTINUED DOUBLE-DIGIT GROWTH Maintaining Double-Digit Growth as Drivers Transition Over Time TODAY NEAR-TERM MID-TERM • Growth driven by diversified product portfolio HYALURONIC ACID • Current growth drivers largely focused on legacy CURRENT BONE GRAFT SUBSTIT
Slide 7: Operating Margin Growth
Innovations For Active Healing OPERATING MARGIN GROWTH Multiple Levers to Drive Margin Expansion ahead of Sales Growth LEVERAGE REVENUE INTEGRATION CONTINUOUS CONSOLIDATE GROWTH SYNERGIES IMPROVEMENT OPERATIONS Focus on Enhancing Operating Margins
Slide 8: 2022 Priorities
Innovations For Active Healing 2022 PRIORITIES Deliver Double-Digit • Maintain double-digit growth in Hyaluronic Acid and Bone Graft Substitutes Organic Growth • Enhance growth with product additions from Misonix and Bioness acquisitions Integrate • Complete integration of Bioness in first quarter a
Slide 9: Pain Treatments: Driving Double-Digit HA Growth
Innovations For Active Healing PAIN TREATMENTS: DRIVING DOUBLE-DIGIT HA GROWTH Continued Above Market Growth as 1 and 3 Injection Regimen Increases Market and Share Growth HA Global Sales Growth 2016 - 2021 Growth Strategy Clinically Differentiated2: Durolane 1 Highest Molecular Weight 2 G Go-to-Mar
Slide 10: Surgical Solutions: Driving Double-Digit BGS Growth
Innovations For Active Healing SURGICAL SOLUTIONS: DRIVING DOUBLE-DIGIT BGS GROWTH Continued Above Market Growth from Innovation and Channel Expansion Global Sales Growth 2016 - 2021 Growth Strategy Granules 1 Recent Innovation: OsteoAMP Flowable Putty 2 G Hardware Agnostic Channel Access Sponge 1 2
Slide 11: Restorative Therapies: Accelerating Growth from M&A
Innovations For Active Healing RESTORATIVE THERAPIES: ACCELERATING GROWTH FROM M&A Bolster Legacy Exogen Therapy with Bioness and Misonix Portfolios to Accelerate Growth Leverage Exogen sales force and call point access to introduce Bioness advanced rehabilitation and Misonix wound care products to
Slide 12: M&A Integration and Cost Synergies
Innovations For Active Healing M&A INTEGRATION AND COST SYNERGIES Integration Top Focus Area for Executive Leadership Bioness break-even Timing: Complete profitability achieved ahead Bioness in first quarter and Misonix of schedule: positive adjusted EBITDA contributor by year-end 2022 expected in 2
Slide 13: Potential CartiHeal Acquisition
Innovations For Active Healing POTENTIAL CARTIHEAL ACQUISITION $265 million to be debt financed for purchase mid-2022 upon FDA PMA Approval Clinical Benefits • Demonstrated superior outcomes over the $1.3B Addressable Market current surgical standard of care Microfracture / Debridement • Offers the
Slide 14: Capital Allocation: M&A Key Strategic Pillar
Innovations For Active Healing CAPITAL ALLOCATION: M&A KEY STRATEGIC PILLAR 2022 Focus on Integration and CartiHeal Acquisition • Focused on tuck-in deals STRATEGIC • Fit within existing business with similar call points CRITERIA • Clinically differentiated products • Furthers our global strategy •
Slide 15: Investment Highlights
Innovations For Active Healing INVESTMENT HIGHLIGHTS Sustainable Double-Digit Growth Diversified Portfolio of Future Growth Drivers Commercial Footprint Across Multiple Call Points Accelerating Operating Margins from Synergies and Growth Bolstering Growth and Scale Through Value Creating M&A Focused